Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Melissa Bondy is the inaugural chair of the Department of Epidemiology and Population Health and the Associate Director for Population Sciences at the Stanford Cancer Institute. Before joining Stanford, she was Associate Director of Cancer Prevention and Population Sciences and section chair of Epidemiology and Population Sciences at Baylor College of Medicine. Her research focus is in genetic and molecular epidemiology and is at the forefront of developing innovative ways to assess the roles of heredity and genetic susceptibility in the etiology of cancer and outcomes, primarily brain and breast cancer. Currently, she leads the largest family study of glioma patients, as well as a study of molecular predictors of outcome for glioma patients. She has a strong interest in health disparities and has a current study to investigate the ethnic differences in glioma. She has been working on studying the health effects of exposure to Hurricane Harvey. She serves on the National Cancer Institute’s (NCI) Board of Scientific Advisors, where she provides direct counsel to the Director of the NCI, and is a member of the External Advisory Board for several NCI-designated cancer centers. In 2018, she received the Visiting Scholar Award from the NCI Division of Cancer Epidemiology and Genetics.
Principal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)<br/><br/>Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)<br/><br/>Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023<br/><br/>Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22<br/><br/>Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025